Inari Medical (NARI)
(Delayed Data from NSDQ)
$55.22 USD
+0.32 (0.58%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $55.21 -0.01 (-0.02%) 6:18 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Company Summary
Irvine CA-based Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. The company has two key product portfolio — ClotTriever and FlowTriever. ClotTriever products help in the removal of clot from peripheral blood vessels in patients suffering from deep vein thrombosis (DVT). Meanwhile, its FlowTriever product is the first thrombectomy system, for the treatment of pulmonary embolism (PE).
The ClotTriever portfolio includes ClotTriever Sheath 13F and 16F; ClotTriever; ClotTriever BOLD; ClotTriever XL and Fourth Generation Triever Catheters; and ProTrieve Sheath. The ...
Company Summary
Irvine CA-based Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. The company has two key product portfolio — ClotTriever and FlowTriever. ClotTriever products help in the removal of clot from peripheral blood vessels in patients suffering from deep vein thrombosis (DVT). Meanwhile, its FlowTriever product is the first thrombectomy system, for the treatment of pulmonary embolism (PE).
The ClotTriever portfolio includes ClotTriever Sheath 13F and 16F; ClotTriever; ClotTriever BOLD; ClotTriever XL and Fourth Generation Triever Catheters; and ProTrieve Sheath. The FlowTriever portfolio includes FlowTriever, Triever20 Curve, Triever16 Curve and Fourth Generation Triever Catheters; Intri24 Sheath; Large Bore Aspiration; Large Bore Syringe and Whoosh Mechanism; FlowSaver Blood Return System; and FlowStasis Suture Retention Device.
Apart from VTE products, Inari is also developing new products to target additional indications under its Emerging Therapy portfolio. The company currently has products targeting Chronic Venous Disease (CVD), Small Vessel Thrombosis (SVT), Arterial Thromboembolism and Chronic Limb-Threatening Ischemia (CLTI). The company is developing new products targeting new indications. Inari’s ClotTriever BOLD and RevCore thrombectomy catheter is used for CVD, the InThrill system for SVT and the Artix system for Arterial Thromboembolism. The company acquired LimFlow in 2023 that added the LimFlow system, which includes Crossing Stents, Extension Covered Stent, ARC and V-Ceiver and Vector (Valvulotome), targeting CLTI patients. The LimFlow system is the only FDA-approved product in its category.
During the first quarter, Inari reported revenues of $137 million (95.8% of total revenues) from VTE products. The figure increased 20.3% year over year. Emerging therapy revenues totaled $6 million (4.2% of total revenues), up 184.5% year over year. U.S. sales improved 19.5% year over year to $133.7 million (93.4% of total revenues) during the first quarter. International sales increased 120.1% to $9.5 million (6.6% of total revenues).
2023 at a Glance
In 2023, adjusted loss per share came in at 3 cents, compared with 55 cents in the previous year. Full-year 20232 revenue was $493.6 million, up 28.7% from the previous year.
General Information
Inari Medical, Inc
6001 Oak Canyon Suite 100
Irvine, CA 92618
Phone: 877-923-4747
Fax: NA
Web: http://www.inarimedical.com
Email: ir@inarimedical.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 7/30/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.19 |
Current Year EPS Consensus Estimate | -0.41 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 7/30/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 54.90 |
52 Week High | 71.85 |
52 Week Low | 36.73 |
Beta | 1.01 |
20 Day Moving Average | 715,613.62 |
Target Price Consensus | 66.36 |
4 Week | 19.35 |
12 Week | 42.89 |
YTD | -15.43 |
4 Week | 18.47 |
12 Week | 32.38 |
YTD | -26.73 |
Shares Outstanding (millions) | 58.14 |
Market Capitalization (millions) | 3,191.78 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -550.00% |
vs. Previous Quarter | -620.00% |
vs. Previous Year | 23.27% |
vs. Previous Quarter | 8.40% |
Price/Book | 7.14 |
Price/Cash Flow | 622.63 |
Price / Sales | 6.13 |
6/30/24 | NA |
3/31/24 | -1.65 |
12/31/23 | 1.23 |
6/30/24 | NA |
3/31/24 | -1.23 |
12/31/23 | 0.97 |
6/30/24 | NA |
3/31/24 | 2.71 |
12/31/23 | 3.09 |
6/30/24 | NA |
3/31/24 | 2.19 |
12/31/23 | 2.52 |
6/30/24 | NA |
3/31/24 | -1.42 |
12/31/23 | 1.11 |
6/30/24 | NA |
3/31/24 | -4.54 |
12/31/23 | -0.33 |
6/30/24 | NA |
3/31/24 | -2.04 |
12/31/23 | 0.86 |
6/30/24 | NA |
3/31/24 | 7.69 |
12/31/23 | 8.07 |
6/30/24 | NA |
3/31/24 | 1.54 |
12/31/23 | 1.49 |
6/30/24 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |